Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: A propensity score‐based weighting

Kondo, Masaaki; Morimoto, Manabu; Ishii, Tomohiro; Nozaki, Akito; Fukuda, Hiroyuki; Numata, Kazushi; Kobayashi, Satoshi; Ohkawa, Shinichi; Hidaka, Hiroyoshi; Nakazawa, Takahide; Shibuya, Akitaka; Okuse, Chiaki; Suzuki, Michihiro; Sakamaki, Kentaro; Morita, Satoshi; Maeda, Shin; Tanaka, Katsuaki

doi:10.1111/1751-2980.12221

Cited by 15 publications

(25 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HAIC has been widely used in Japan [12]. For TACErefractory HCC, HAIC presents a satisfactory therapeutic effect [19,20]. Sorafenib, as the first-line drug for advanced HCC, also has good efficacy in the treatment of TACE-refractory HCC [24,30,31].…”

Section: Discussionmentioning

confidence: 99%

“…All of the patients in 4 studies [20,[23][24][25] had no extrahepatic metastasis, while Moriya et al included patients with extrahepatic metastasis. And the proportion of patients with extrahepatic metastasis included in Moriya et al' s study [26] was significantly different between the two groups (5% vs. 80%, p<0.01).…”

Section: Discussionmentioning

confidence: 99%

“…A total of 260 records were retrieved. Five articles [20,[23][24][25][26] and 583 patients were involved in the metaanalysis. The detail of the literature selection process was presented in Figure 1.…”

Section: Eligible Studiesmentioning

confidence: 99%

“…Four included articles [20,[23][24][25] reported the HR and 95%CI of OS in the HAIC group compared with the sorafenib group. The HR and 95%CI of 1 article were obtained from the survival curve [26].…”

Section: Osmentioning

confidence: 99%

“…Although HAIC or sorafenib were both recommended for the TACE-refractory HCC [14], the knowledge as to which regimen is better or which one carries the more prolonged overall survival (OS) lacks the support of evidence-based medicine. Currently, several studies have compared the efficacy of HAIC and sorafenib in the treatment of TACE-refractory HCC, but but the conclusion is inconsistent [20,21]. To compare the clinical effectiveness of HAIC with sorafenib in the treatment of TACE-refractory HCC, we conducted this study.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Sorafenib is more effective in the treatment of TACE-refractory hepatocellular carcinoma than hepatic arterial infusion chemotherapy: a meta-analysis

Wang¹,

Tang²,

Long³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Currently, several studies have compared the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in the treatment of TACE-refractory hepatocellular carcinoma (HCC), but the conclusion is inconsistent. The purpose of this meta-analysis was to compare the effectiveness of sorafenib and HAIC in patients with TACE-refractory HCC.Methods Multi-databases were searched to identify relevant studies published from inception to March 2020. The quality evaluation and data extraction were carried out for the selected articles meeting the inclusion and exclusion criteria. The data was analyzed using STATA16.Results Five studies with 583 patients were included. Although the objective response rate in the HAIC group was significantly higher than that in the sorafenib group (RR = 3.08, 95%CI [1.38, 6.87], p=0.006), the overall survival (OS) was significantly shorter than that in the patients receiving sorafenib treatment (HR = 1.69, 95% CI [1.09, 2.62], p=0.018). Progression-free survival (HR = 1.21, 95% CI [0.76, 1.92], p=0.426) and disease control rate (RR = 0.94, 95% CI [0.60, 1.48], p=0.798) were not significantly different between the two groups.Conclusion Compared with HAIC, patients with TACE- refractory HCC in the sorafenib group can obtain significantly longer OS. Sorafenib may be more suitable for the treatment of patients with TACE-refractory HCC. High-quality evidence is needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Eligible Studiesmentioning

confidence: 99%

Section: Osmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Sorafenib is more effective in the treatment of TACE-refractory hepatocellular carcinoma than hepatic arterial infusion chemotherapy: a meta-analysis

Wang¹,

Tang²,

Long³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization

et al. 2017

View full text Add to dashboard Cite

show abstract

Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis

et al. 2015

View full text Add to dashboard Cite

BackgroundSorafenib might prevent hepatocellular carcinoma (HCC) recurrence caused by the promotion of neoangiogenesis after transarterial chemoembolization (TACE).ObjectivesTo evaluate the efficacy and safety of TACE followed by sorafenib for treating advanced HCC.Patients and MethodsWe retrospectively analyzed 95 advanced HCC patients treated with TACE between July 2008 and December 2012 at our institution. Twenty-four patients received TACE followed by sorafenib within 14 days (S-TACE) and 71 received TACE alone. Progression-free survival (PFS) and cumulative survival from the time of non-responsiveness to TACE were compared between groups and predictive factors for PFS were analyzed.ResultsThe median patient age was 72.2 years and 74 patients were male (77.9 %). Although median tumor size was similar between groups, the mean tumor number was significantly higher in the S-TACE versus TACE-alone group (16 vs. 8, P = 0.04). The number of prior treatments was significantly higher in the S-TACE group. Other baseline variables were similar. There were two severe adverse events in the S-TACE group and none in the TACE-alone group. Median PFS (189 vs. 106 days, P = 0.02) and median overall survival time (861 vs. 467 days, P = 0.01) from the time of non-responsiveness to TACE were significantly longer with S-TACE than TACE alone. Adjusting for significant factors in univariate analysis, multivariate analysis indicated that sorafenib administration, tumor size, and alanine transaminase were independent predictors of PFS.ConclusionTACE followed by sorafenib significantly improved PFS and survival in patients with advanced HCC unresponsive to TACE.

show abstract

Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: A propensity score‐based weighting

Abstract: HAIC with cisplatin can be an alternative treatment for the selection of HCC patients who have not responded to prior TACE and cannot tolerate sorafenib.

Cited by 15 publications

References 25 publications

Sorafenib is more effective in the treatment of TACE-refractory hepatocellular carcinoma than hepatic arterial infusion chemotherapy: a meta-analysis

Sorafenib is more effective in the treatment of TACE-refractory hepatocellular carcinoma than hepatic arterial infusion chemotherapy: a meta-analysis

Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization

Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis

Contact Info

Product

Resources

About